Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Absci Corporation (ABSI : NSDQ)

• Company Description    Absci Corporation is a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design. Absci Corporation is based in NEW YORK. Number of Employees: 140

• Price / Volume Information    Yesterday's Closing Price: $2.78 Daily Weekly Monthly 20 Day Moving Average: 4,371,028 shares Shares Outstanding: 153.02 (millions) Market Capitalization: $425.40 (millions) Beta: 2.12 52 Week High: $5.23 52 Week Low: $2.01 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 1.46% 9.59% 12 Week -22.99% -17.07% Year To Date -20.34% -14.38%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 18105 SE MILL PLAIN BLVD - VANCOUVER,WA 98683 USA ph: 360-949-1041 fax: - investors@absci.com http://www.absci.com

• General Corporate Information    Officers Sean McClain - Chief Executive Officer and Director Frans van Houten - Chairmam Zachariah Jonasson - Chief Financial Officer Todd Bedrick - Chief Accounting Officer Prof Sir Menelas Pangalos - Director Peer Information Absci Corporation (CORR.) Absci Corporation (RSPI) Absci Corporation (CGXP) Absci Corporation (BGEN) Absci Corporation (GTBP) Absci Corporation (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00091E109 SIC: 8731 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/12/26 Share - Related Items Shares Outstanding: 153.02 Most Recent Split Date: (:1) Beta: 2.12 Market Capitalization: $425.40 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.19 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.70 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.21 Price/Cash Flow: - Price / Sales: 151.93 EPS Growth vs. Year Ago Period: 8.00% vs. Previous Quarter: -15.00% Sales Growth vs. Year Ago Period: -2.26% vs. Previous Quarter: 71.96% ROE 12/31/25 - -62.33 09/30/25 - -60.19 06/30/25 - -60.21 ROA 12/31/25 - -53.24 09/30/25 - -50.88 06/30/25 - -50.85 Current Ratio 12/31/25 - 6.57 09/30/25 - 5.89 06/30/25 - 4.39 Quick Ratio 12/31/25 - 6.57 09/30/25 - 5.89 06/30/25 - 4.39 Operating Margin 12/31/25 - -4,295.86 09/30/25 - -4,071.19 06/30/25 - -2,737.94 Net Margin 12/31/25 - -4,113.68 09/30/25 - -4,071.19 06/30/25 - -2,737.94 Pre-Tax Margin 12/31/25 - -4,111.21 09/30/25 - -4,062.24 06/30/25 - -2,733.47 Book Value 12/31/25 - 1.26 09/30/25 - 1.41 06/30/25 - 1.36 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - 0.00 09/30/25 - 0.03 06/30/25 - 0.09

Powered by Zacks Investment Research ©